News & Media

World Stroke Day 2026 – Research Across the Network

29th October 2026

29 October marks World Stroke Day.

Stroke causes around 34,000 deaths each year in the UK and remains the leading cause of severe disability. With around one in four people expected to experience a stroke during their lifetime, its impact is felt by millions of individuals, families and communities across the country.

Clinical trials play a vital role in advancing stroke prevention, treatment and recovery, helping to improve outcomes for patients now and in the future. Below, we highlight some of the many stroke studies being undertaken across the UK Registered Clinical Trials Unit (CTU) Network and the contribution they are making to stroke research.

Find out more about the importance of stroke research here.


The ASPIRING Study – Antiplatelet Secondary Prevention International Randomised study after INtracerebral haemorrhaGe

The ASPIRING Study aims to produce reliable information about whether aspirin or clopidogrel help people after brain haemorrhage.

Many strokes and heart attacks that happen after brain haemorrhage are caused by blood clots, so aspirin or clopidogrel might help to prevent them. However, doctors aren’t sure whether aspirin or clopidogrel can be used for people who have had a brain haemorrhage.

ASPIRING Logo - World Stroke Day CTU Research 2026

ASPIRING will be the largest and most reliable study of aspirin and clopidogrel after brain haemorrhage and will involve more than four thousand people worldwide.

This study aims to produce reliable information about whether aspirin or clopidogrel help people after brain haemorrhage. The findings of ASPIRING could affect how doctors treat people with brain haemorrhage in everyday medical practice worldwide in the future. If ASPIRING shows that aspirin or clopidogrel works, this could prevent another major vascular event for thousands of brain haemorrhage survivors worldwide each year.

The Chief Investigator, Prof. Rustam Al-Shahi Salman of the Edinburgh CTU, also leads the Research to Understand Stroke due to Haemorrhage (RUSH) programme, which is dedicated to improving the outcome for adults who have diseases that may cause, or have caused, intracranial haemorrhage.

Learn more about the ASPIRING study here.


The COMMITS Study – Confirming the Mechanism of Motivational Interviewing Therapy after Stroke

Depression affects around one-third of stroke survivors and is associated with poorer recovery, increased morbidity and reduced quality of life. Evidence for effective early psychological interventions after stroke remains limited. COMMITS (Confirming the Mechanism of Motivational Interviewing Therapy after Stroke) was a large multicentre randomised controlled trial led by Professor Liz Lightbody, evaluating whether a Motivational Interviewing-Based Intervention (MIBI) could reduce depressive symptoms and support psychological recovery after stroke.

Funded by NIHR and NHS SQUIRES, COMMITS recruited 1,246 participants across 16 UK stroke units, making it one of the largest trials of psychological support after stroke. Participants were randomised to receive MIBI, an attention control intervention or usual care. The study evaluated the impact of these approaches on mood, quality of life, functional outcomes and healthcare costs. Results showed that participants receiving MIBI experienced a small but statistically significant reduction in depressive symptoms compared with usual care, providing evidence that early psychological support may help improve emotional recovery after stroke.

The findings advance understanding of how psychological support can be integrated into routine stroke care alongside physical rehabilitation. While no differences were found in functional outcomes, quality of life or cost-effectiveness, the study highlights the potential value of motivational interviewing as an early intervention and provides an important foundation for future research and service development. Alongside the trial, an embedded process evaluation explored participants’ and staff experiences of delivering and receiving the intervention, providing valuable insights into the acceptability, delivery and implementation of psychological support within routine NHS stroke services. Primary results were presented at the European Stroke Organisation Conference in 2026 and published in the European Stroke Journal.

The Lancashire Clinical Trials Unit played a pivotal role in the design, conduct and management of COMMITS, providing expertise in trial methodology, project management, data management, statistical analysis, governance and regulatory oversight. The CTU coordinated recruitment and trial delivery across all 16 stroke units, ensuring high-quality data collection and the consistent implementation of a complex behavioural intervention.

Further information:


The TRICEPS Trial – TRanscutaneous lImb reCovEry Post-Stroke

Many stroke survivors are left with arm weakness which can make daily activities difficult. Although rehabilitation therapy does help after a stroke, the benefits are small. 

Researchers in Sheffield are testing a new, non-invasive treatment to help people recover arm movement after a stroke. Previous research showed that stimulating the vagus nerve while people performed arm exercises improved recovery, but that approach required surgery to implant a device and treatment in hospital and patients had to go into hospital for a therapist to trigger the stimulation.

TRICEPS Trial - World Stroke Day CTU Research 2026

The TRICEPS trial, which is funded by the National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) Programme, aims to determine whether the effects of rehabilitation therapy for arm recovery after stroke can be enhanced with a treatment called Transcutaneous Vagus Nerve Stimulation (TVNS). TVNS is a non-invasive way of stimulating the VN which does not involve either surgery or anaesthesia. The VN has a branch that goes to the ear which can be stimulated through the skin, using a small earpiece.

Participants have been randomised to receive self-delivered rehabilitation therapy and TVNS or self-delivered rehabilitation therapy and sham TVNS. In some cases, participants will also undertake activities of daily living (ADLs). Participants will be blinded to which treatment they receive.

Recruitment for the TRICEPS trial has now closed and the trial results will become available after July 2027.

Find out more about the TRICEPS trial here.


The NOVEL Trial – NanO2 in Large VessEL Occlusion Stroke

NOVEL is a randomised, blinded, prospective, parallel group, multicentre controlled trial investigating whether an oxygen-carrying perfluorocarbon, DDFPe (NanO2), increases the volume of ischaemic brain tissue that survives, is safe and well-tolerated, and improves neurological and functional outcomes in participants with acute LVO stroke and significant penumbra on perfusion imaging. The primary objective is the volume of ischaemic tissue salvaged at follow-up imaging, measured at 24-72hrs post treatment.

Novel Trial - World Stroke Day CTU Research 2026

The trial is being led in Glasgow by Professor Keith Muir, SINAPSE Professor of Clinical Imaging and Consultant Neurologist. It is co-sponsored by NHS Greater Glasgow and Clyde and the University of Glasgow. Funding is provided by the NIHE EME programme with IMP provided by NuvOx Pharma.

Stroke due to large vessel occlusion accounts for around 10% of all stroke, but around 90% of all mortality and 66% of all disability due to stroke. Despite considerable progress in management, delays to effective reperfusion are common, both for intravenous thrombolysis (median door-to-needle time in UK hospitals typically around 50 minutes) and for endovascular thrombectomy (54% of all patients in SSNAP 2022-23 data were inter-hospital transfers, with median onset to arterial puncture time of just over 3 hours). In addition, reperfusion treatments are not always effective, and around 40-50% of patients have disability despite receiving these treatments. There is therefore a considerable clinical need for treatments that may retard the evolution of ischaemic damage to the brain. The strategy under investigation in NOVEL involves an oxygen-carrying perfluorocarbon molecule that has potential to be deployed in pre-hospital or primary stroke care settings without the safety concerns attendant with other agents under development.

Glasgow Clinical Trials Unit (GCTU) and the Robertson Centre for Biostatistics (RCB) play a key role in supporting the NOVEL trial through trial management, data management, provision of the data capture and randomisation tools, and statistical and methodological expertise. Dr Theo Pepler serves as the Trial Statistician.

Learn more about the NOVEL trial here.


ID-STROKE: The Identification of Stroke aetiology to Reduce reoccurrence of stroke

Almost 40% of stroke survivors experience another stroke within 10 years, yet around one-third never receive a confirmed explanation for why their stroke occurred. Accurate identification of stroke aetiology is essential to guide targeted secondary prevention, but current investigation pathways vary across the UK and are not supported by a consistent evidence base.

The ID-STROKE programme, funded by The Burdett Trust for Nursing, is investigating how stroke aetiology is identified in clinical practice and where opportunities exist to improve care. The programme has recently completed a UK-wide clinician survey and a multi-site clinical audit across three North West stroke units to explore current investigation pathways, diagnoses and outcomes. Early findings suggest significant variation in the investigations undertaken and the causes assigned, highlighting the need for a more standardised approach to stroke aetiology assessment.

ID-STROKE - World Stroke Day CTU Research 2026

By improving understanding of current practice, this work aims to support the development of evidence-based pathways for identifying stroke causes, enabling more personalised secondary prevention and potentially reducing the risk of recurrent stroke for patients.

The Lancashire Clinical Trials Unit (CTU) has been integral to the delivery of the programme, leading the statistical analyses, designing and maintaining the REDCap database used for data collection, and undertaking data quality and fidelity checks. Through its expertise in study design, data management and analysis, the CTU has ensured the robust collection and evaluation of data needed to generate reliable evidence to inform future stroke care.

Find out more about the ID-STROKE programme and research team here.


The ASPIRE Study – Atrial Fibrilation Screening to Prevent

The ASPIRE study is an investigation into determining people’s risk of Atrial Fibrilation (AF) with the idea of preventing them from having an AF-related stroke. The overall research aim is to develop a model to inform an AF screening programme.

Stroke Association - World Stroke Day CTU Research 2026

Atrial fibrillation (AF) can cause ischaemic stroke, but population AF screening is not yet recommended. In 2024 3,650 deaths in Scotland were caused by cerebrovascular disease including stroke, 6% of all deaths. 20%-25% of strokes are caused by AF, largely undiagnosed. A targeted screening programme for AF followed by protective treatment where AF is identified has the potential to save lives.

Working in partnership with a panel of stroke patients, researchers analysed demographics, lifestyle factor, and biochemical data from people without prior AF in the Generation Scotland study, with external validation in UK Biobank. Electronic record linkage identified people with AF during follow-up. They then developed and externally validated binary classification models intended to guide AF screening using Lasso regression.

The process produced a simple model with age, body weight, history of ischaemic heart disease and heart failure as predictors. These represent information that would be readily available in a primary care setting, making them suitable for use in a screening programme. The model could be used to help guide AF screening in the general population to prevent AF-related strokes. A health economic analysis concluded that AF screening could have the potential to save money as well as lives.

The ASPIRE study is funded by a Stroke Association donation: ASPIRE: The Betty Carr Atrial Fibrillation Screening Study.

Learn more about the ASPIRE study here.


The CLASP Trial – CLArithromycin for post-Stroke Pneumonia

CLArithromycin for post-Stroke Pneumonia (CLASP) is a phase III prospective, randomised, open-label, blinded-endpoint clinical trial investigating whether adding a course of clarithromycin to usual treatment for post-stroke pneumonia (PSP) improves recovery and participant outcomes. The primary objective of the trial is to determine whether treatment with clarithromycin in addition to usual non-macrolide antibiotic treatment improves functional outcome at 90 days in comparison to usual antibiotic treatment. This is measured using the modified Rankin Scale (mRS).

CLASP Trial - World Stroke Day CTU Research 2026

CLASP is funded by the NIHR HTA programme, involves 45 NHS sites in all four countries of the UK and plans to recruit 1166 participants and their caregivers. It is led by Profs Craig J Smith and Jesse Dawson and is co-sponsored by NHS Greater Glasgow and Clyde and the University of Glasgow, in collaboration with the University of Manchester.

Around 100,000 people in the UK have a stroke each year, and pneumonia occurs in about 1 in 10 of these people in the first week after stroke. Post-stroke pneumonia is a common and serious complication that can adversely affect recovery, increase disability, prolong hospital stays and increase mortality. CLASP aims to determine whether clarithromycin’s additional anti-inflammatory and immunomodulatory effects can improve functional outcomes at 90 days after stroke. If successful, CLASP could provide evidence that adding clarithromycin to usual non-macrolide antibiotic treatment improves recovery and functional outcomes for patients who develop post-stroke pneumonia, which would change clinical practice.

The Robertson Centre for Biostatistics (RCB) and Glasgow Clinical Trials Unit (GCTU), plays a key role in delivering CLASP by providing coordinated trial management, data management, eCRF, database and systems development, randomisation and statistical support services. GCTU trial managers support participating sites through set-up, training, recruitment and delivery. Data security and integrity is ensured via RCB systems which are fully validated in accordance with industry and regulatory standards and are developed in accordance to strictly controlled procedures. The CTU model enables efficient and effective management of this large multi-centre trial, supporting the generation of robust evidence, with the aim of informing future stroke care.

To learn more about the CLASP trial, please click here.


Find out more about the importance of stroke research here.

More News

form

Get in touch

If you have any questions about the site, please feel free to contact us. We are always looking for ways to better serve our members - YOU are important to us!

(0113) 3439132

    Sign up to newsletter

    form

    Get in touch

    If you have any questions about the site, please feel free to contact us. We are always looking for ways to better serve our members - YOU are important to us!

    (0113) 3439132

      Sign up to newsletter